News | May 28, 2025
Granules India posts Q4 FY25 PAT at Rs. 152 Cr
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
New Board of Directors and management team at Suven Pharma also appointed
API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24
One batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled
Subscribe To Our Newsletter & Stay Updated
